Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small cell lung carcinoma (SCLC) is characterized by high metastatic rate and poor
prognosis. The platinum-based chemotherapy still represents the backbone of the therapy; …

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early
metastasis and extreme lethality. The backbone of SCLC treatment over the past several …

Small cell lung cancer (SCLC) is a lethal form of lung cancer. Here, we develop a
quantitative multiplexed approach on the basis of lentiviral barcoding with somatic CRISPR …

Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options.
Bromodomain and extraterminal domain inhibitors (BETis) have shown promising preclinical …

Background COTE-1 has been found to promote the proliferation and invasion of non-small
cell lung cancer. However, the mechanism of COTE-1 in SCLC is still unclear. Exploring the …

Small cell lung carcinoma (SCLC) is among the most lethal of all solid tumor malignancies.
In an effort to identify novel therapeutic approaches for this recalcitrant cancer type, we …

Small cell lung cancer (SCLC) has a poor prognosis, emphasizing the necessity for
developing new therapies. The de novo synthesis pathway of purine nucleotides, which is …

Simple Summary Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer,
is mostly associated with smoking and has a low survival rate. Among the different …

Lung cancer has become a major public health concern, standing as the leading cause of
cancer-related deaths worldwide. Among its subtypes, small-cell lung cancer (SCLC) is …